Christopher O Barnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8499925/publications.pdf

Version: 2024-02-01

394286 642610 9,271 23 19 23 citations g-index h-index papers 35 35 35 14983 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. Cell Reports, 2022, 38, 110348.	2.9	14
2	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	13.7	1,355
3	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science, 2021, 371, 735-741.	6.0	305
4	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	13.7	1,232
5	Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation. Nature Communications, 2021, 12, 1950.	5 . 8	22
6	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	13.7	108
7	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	13.7	610
8	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	13.5	73
9	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	5.8	332
10	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 2021, 12, 4886.	5 . 8	65
11	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	6.6	230
12	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	2.9	80
13	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533.	5. 8	27
14	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687.	13.7	1,346
15	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	13.7	1,742
16	De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science, 2020, 370, 1208-1214.	6.0	172
17	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	13.5	724
18	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	13.5	106

#	Article	IF	CITATIONS
19	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, .	2.8	10
20	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	6.6	85
21	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	13.7	145
22	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nature Communications, 2018, 9, 1251.	5.8	85
23	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host and Microbe, 2018, 24, 579-592.e4.	5.1	88